Feedback
Settings

Settings

Goto Application

1,920 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(GRYSXUXXBDSYRT-WOUKDFQISA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 192
1.WO/2026/017864TREATMENT OF OSTEOARTHRITIS AND/OR RHEUMATOID ARTHRITIS WITH PRO-CHONDROGENIC AND/OR CHONDROCYTE PROTECTIVE FACTORS
WO - 22.01.2026
Int.Class C12N 5/0775
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775Mesenchymal stem cells; Adipose-tissue derived stem cells
 Appl.No PCT/EP2025/070674 Applicant SMARTCELLA SOLUTIONS AB Inventor YANG, Ran
The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and/or chondrocyte protective factor. The pro-chondrogenic and/or chondrocyte protective factor can be TGFβ3.
2.WO/2026/018181IMMUNOGENIC COMPOSITIONS AND USES THEREOF
WO - 22.01.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/IB2025/057203 Applicant PFIZER INC. Inventor HUANG, Bridget Yih Jiin
The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.
3.WO/2026/019922USES OF LIPID NANOPARTICLES CONTAINING CRISPR-ASSOCIATED PROTEINS (CAS) AND GUIDE RNA IN MANAGING VIRAL INFECTIONS
WO - 22.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/US2025/037913 Applicant EMORY UNIVERSITY Inventor SANTANGELO, Philip J.
Disclosed herein are compositions and methods for managing viral infections. In certain embodiments, this disclosure relates to compositions that specifically cleave target sequences in viruses, such as dengue virus. Such compositions include lipid nanoparticles containing nucleic acids encoding a Cas guide-RNA associated endonuclease, with a guide sequence of a viral target sequence. In certain embodiments, contemplated methods include treating a viral infection by administering lipid nanoparticles (LNPs) comprising mRNA encoding Cas13a and a guide RNA or multiple guide RNAs that target regions of a dengue genome or other viral genome.
4.WO/2026/019998VACCINES FOR KAPOSI'S SARCOMA-ASSOCIATED HERPESVIRUS
WO - 22.01.2026
Int.Class A61K 39/245
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
245Herpetoviridae, e.g. herpes simplex virus
 Appl.No PCT/US2025/038046 Applicant THE CLEVELAND CLINIC FOUNDATION Inventor JUNG, Jae
Provided herein are compositions, systems, kits, and methods for immunizing a subject against Kaposi's sarcoma-associated herpesvirus (KSHV) with a composition: i) comprising a plurality of nanoparticles self-assembled from a plurality of fusion proteins that comprise: a) at least a portion of a Ferritin protein, and b) an immunogenic protein comprising at least a portion of: KSHV K8.1 protein, or ii) polynucleotides encoding said fusion proteins (e.g., human codon optimized mRNA sequences present in lipid nanoparticles). In other embodiments, provided herein are compositions, systems, and kits, and methods for immunizing a subject against KSHV employing a human codon optimized nucleic acid sequence (e.g., mRNA) encoding a KSHV K8.1 protein.
5.WO/2026/017857TREATMENT OF OSTEOARTHRITIS AND/OR RHEUMATOID ARTHRITIS WITH PRO-CHONDROGENIC AND/OR CHONDROCYTE PROTECTIVE FACTORS
WO - 22.01.2026
Int.Class C12N 5/0775
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07Animal cells or tissues
071Vertebrate cells or tissues, e.g. human cells or tissues
077Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
0775Mesenchymal stem cells; Adipose-tissue derived stem cells
 Appl.No PCT/EP2025/070648 Applicant SMARTCELLA SOLUTIONS AB Inventor YANG, Ran
The present disclosure relates to mesenchymal stem cells (MSCs) for use in a method of treatment of arthritis. The MSCs are transfected with an mRNA construct encoding a pro-chondrogenic and/or chondrocyte protective factor. The pro-chondrogenic and/or chondrocyte protective factor can be WNT3a.
6.WO/2026/014855FUSION PROTEIN COMPRISING APOLIPOPROTEIN AND FC REGION-BINDING PEPTIDE AND USES THEREOF
WO - 15.01.2026
Int.Class C07K 14/775
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
775Apolipopeptides
 Appl.No PCT/KR2025/009774 Applicant RNAGENE INC. Inventor LEE, Woo Ghil
The present invention relates to a fusion protein and a use thereof, wherein the fusion protein comprises: an apolipoprotein or a fragment thereof; and an Fc-binding peptide (Fc BP) or a fragment thereof. According to one aspect, a lipid carrier comprising the fusion protein was found to exhibit remarkably improved targeting efficiency, and thus can be used to deliver an active substance to a desired target.
7.20260014258PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
US - 15.01.2026
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No 19335735 Applicant ModernaTX, Inc. Inventor Mohindra SEEPERSAUD

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

embedded image

8.WO/2026/015876IMPROVED METHODS FOR IN VITRO TRANSCRIPTION
WO - 15.01.2026
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No PCT/US2025/037414 Applicant ARCTURUS THERAPEUTICS, INC. Inventor HILL, Brett Dallas
Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced RNA degradation.
9.20260015641METHODS FOR IN VITRO TRANSCRIPTION
US - 15.01.2026
Int.Class C12P 19/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
19Preparation of compounds containing saccharide radicals
26Preparation of nitrogen-containing carbohydrates
28N-glycosides
30Nucleotides
34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
 Appl.No 19267305 Applicant ARCTURUS THERAPEUTICS, INC. Inventor Brett Dallas HILL

Disclosed herein are methods of producing transcribed RNA product with increased yield and reduced RNA degradation.

10.20260014281PEG TARGETING COMPOUNDS FOR DELIVERY OF THERAPEUTICS
US - 15.01.2026
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No 19335496 Applicant ModernaTX, Inc. Inventor Mohindra SEEPERSAUD

Provided herein are targeting compounds (e.g., a compound of Formula I, a stereoisomer thereof, a tautomer thereof, and/or a pharmaceutically acceptable salt thereof), lipid nanoparticle (LNP) compositions comprising such targeting compounds and the use thereof. The LNP compositions described herein may further comprise one or more selected from ionizable lipids, PEG-lipids, phospholipids, and structural lipids.

embedded image

# -